In Entwicklung und Produktion entscheidet sich der Wettbewerb

Ewers, Christian L. J.; Küppers, Stephan

doi:10.1002/nadc.20020501117

Cited by 3 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1) in an average pharmaceutical enterprise [8,9]. If it is assumed that also part of the administration and marketing can be included in the production sector, then it rapidly becomes apparent that production represents the largest single cost factor in real terms.…”

Section: Reduction Of Manufacturing Costs As a Starting Pointmentioning

confidence: 99%

New Developments in Chemical Engineering for the Production of Drug Substances

Behr

Brehme

Ewers³

et al. 2004

Engineering in Life Sciences

Self Cite

View full text Add to dashboard Cite

The pharmaceutical industry is moving towards a profitability gap between increasing costs and decreasing prices. Finally, management has understood that mergers and acquisitions, high throughput screening, and biotechnology alone will not save the companies' earnings. Therefore, classical approaches like the optimization of production technologies for drug substances, that might help to increase profitability, are receiving increasing attention. This paper shows how the combination of innovative components will guide the way to very efficient and cost-effective production. The first component is the design and manufacturing of production facilities. The second component is a process streamlining of the production process. The key technologies discussed here are process control and miniplant technology. For these technologies a brief outlook on future trends is given.

show abstract

Section: Reduction Of Manufacturing Costs As a Starting Pointmentioning

confidence: 99%

New Developments in Chemical Engineering for the Production of Drug Substances

Behr

Brehme

Ewers³

et al. 2004

Engineering in Life Sciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…30 % der Gesamtkosten (s. Abb. 1) in einem durchschnittlichen Pharmaunternehmen dar [8,9]. Wenn man davon ausgeht, dass auch ein Teil der Verwaltung und des Marketings der Produktion zuzurechnen sind, liegt die Erkenntnis nahe, dass die Produktion real den gröûten Einzelkostenbeitrag darstellt.…”

Section: Reduzierung Der Herstellkosten Als Ansatzpunktunclassified

Neue Entwicklungen bei Anlagen und Verfahren für die Produktion von Pharmawirkstoffen

Behr

Brehme

Ewers³

et al. 2003

Chemie Ingenieur Technik

Self Cite

View full text Add to dashboard Cite

Die Pharmaindustrie befindet sich auf dem Weg in die Kostenfalle. Mehr und mehr setzt sich die Erkenntnis durch, dass klassische Stärken der Optimierung von Produktionstechnologien dort ansetzen können, wo Fusionen, Investitionen in High‐Through‐Put‐Screening und Biotechnologie bisher nicht die nötigen Erfolge gezeigt haben. Im vorliegenden Beitrag wird gezeigt, wie aus einer Kombination von innovativen Bausteinen eine leistungsfähige und deutlich kostengünstigere Produktion von Pharmawirkstoffen resultiert. Diese kann den Ausweg aus der Kostenfalle weisen. Ein erster Baustein, der betrachtet werden soll, ist der Anlagenbau, daneben ist eine deutlich stärkere Prozessorientierung als zweiter Baustein zu sehen. Die Technologien, die den dritten Baustein der neuen Produktionswege für Pharmawirkstoffe darstellen, sind die Miniplant‐Technologie und die Prozessanalytik. Zu letzterem technologischen Baustein werden anhand von Beispielen die Trends der Zukunft aufgezeigt.

show abstract

“…By contrast, traditional batch production plants have been flexible towards product changes, requiring lower capital investment and utilizing small discrete steps to the changing of manufacturing quantity schemes. Therefore, from a manufacturing perspective there is a challenge to evolve with a new continuous processing answer to the target of uniting the traditional logistic convenience of batch production with the advantages of continuous processing. A significant boundary condition for a continuous manufacturing strategy for compounds demands that a manufacturing process can be set up before quality specification such as those required in the drug master file.…”

Section: Introductionmentioning

confidence: 99%

Novel Innovation Systems for a Cellular Approach to Continuous Process Chemistry from Discovery to Market

Schwalbe¹,

Autze²,

Hohmann³

et al. 2004

Org. Process Res. Dev.

125

View full text Add to dashboard Cite

Continuous processing of liquid/liquid synthesis and microreaction technology are shown to reduce the cost of process development and manufacturing of active pharmaceutical ingredients and other functional molecules on a commercial scale. Combinatorial synthesis systems for continuous chemistry are introduced, and their applications are described. Reactions within these systems scale seamlessly in standardized commercial continuous synthesis equipment allowing rapid access to kilogram quantities of advanced intermediates. Chemical and process development within such systems are illustrated by a case study of a continuous multistep process. Additionally, another case study shows the benefit of microreaction technology in the manufacture of high value added functional chemicals.

show abstract

In Entwicklung und Produktion entscheidet sich der Wettbewerb

Cited by 3 publications

References 2 publications

New Developments in Chemical Engineering for the Production of Drug Substances

New Developments in Chemical Engineering for the Production of Drug Substances

Neue Entwicklungen bei Anlagen und Verfahren für die Produktion von Pharmawirkstoffen

Novel Innovation Systems for a Cellular Approach to Continuous Process Chemistry from Discovery to Market

Contact Info

Product

Resources

About